All equity acquisition adds short-acting psilocin candidate for broad range of indications to Beckley Psytech’s portfolio of psychedelic assets Expanded clinical pipeline will deliver multiple value inflection points over next 18 months Phase 1 single ascending dose study of ELE-101 to initiate before the end of 2022 Lead 5-MeO-DMT formulation BPL-003 selected for upcoming Phase 2 studies in…


Previous articleSilo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Next articleAlgernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study